MYRIAD GENETICS
MYRIAD GENETICS operates in Diversified Metals & Mining.
MYRIAD GENETICS (MYD) - Total Assets
Latest total assets as of September 2024: €1.08 Billion EUR
Based on the latest financial reports, MYRIAD GENETICS (MYD) holds total assets worth €1.08 Billion EUR as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
MYRIAD GENETICS - Total Assets Trend (2016–2024)
This chart illustrates how MYRIAD GENETICS’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
MYRIAD GENETICS - Asset Composition Analysis
Current Asset Composition (June 2024)
MYRIAD GENETICS's total assets of €1.08 Billion consist of 27.4% current assets and 72.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 11.5% |
| Accounts Receivable | €114.30 Million | 10.0% |
| Inventory | €22.00 Million | 1.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €349.50 Million | 30.5% |
| Goodwill | €287.40 Million | 25.1% |
Asset Composition Trend (2016–2024)
This chart illustrates how MYRIAD GENETICS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MYRIAD GENETICS's current assets represent 27.4% of total assets in 2024, a decrease from 35.7% in 2016.
- Cash Position: Cash and equivalents constituted 11.5% of total assets in 2024, up from 7.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 55.0% of total assets, an increase from 47.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 30.5% of total assets.
MYRIAD GENETICS Competitors by Total Assets
Key competitors of MYRIAD GENETICS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
MYRIAD GENETICS - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - MYRIAD GENETICS generates 0.66x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - MYRIAD GENETICS is currently not profitable relative to its asset base.
MYRIAD GENETICS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.90 | 1.27 | 3.25 |
| Quick Ratio | 1.73 | 1.15 | 3.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €138.90 Million | € 56.10 Million | € 252.90 Million |
MYRIAD GENETICS - Advanced Valuation Insights
This section examines the relationship between MYRIAD GENETICS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -4.4% |
| Total Assets | €1.15 Billion |
| Market Capitalization | $53.84K USD |
Valuation Analysis
Below Book Valuation: The market values MYRIAD GENETICS's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: MYRIAD GENETICS's assets decreased by 4.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for MYRIAD GENETICS (2016–2024)
The table below shows the annual total assets of MYRIAD GENETICS from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | €1.15 Billion | -4.35% |
| 2023-06-30 | €1.20 Billion | -9.24% |
| 2022-06-30 | €1.32 Billion | -5.97% |
| 2020-06-30 | €1.40 Billion | -10.12% |
| 2019-06-30 | €1.56 Billion | +33.10% |
| 2018-06-30 | €1.17 Billion | -4.11% |
| 2017-06-30 | €1.22 Billion | +39.06% |
| 2016-06-30 | €880.50 Million | -- |